
- Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018). Centrally acting agents for obesity: past, present, and future. Drugs, 78, 1113-1132.
- Rothman, R. B., & Baumann, M. H. (2000). Neurochemical mechanisms of phentermine and fenfluramine: therapeutic and adverse effects. Drug development research, 51(2), 52-65.
- Kim, K. K., Cho, H. J., Kang, H. C., Youn, B. B., & Lee, K. R. (2006). Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei medical journal, 47(5), 614-625.
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., … & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232.
- Bramante, C. T., Raatz, S., Bomberg, E. M., Oberle, M. M., & Ryder, J. R. (2020). Cardiovascular risks and benefits of medications used for weight loss. Frontiers in Endocrinology, 10, 883.
- Bays, H. E., Lazarus, E., Primack, C., & Fitch, A. (2022). Obesity pillars roundtable: phentermine–Past, present, and future. Obesity Pillars, 3, 100024.
- Lewis, K. H., Fischer, H., Ard, J., Barton, L., Bessesen, D. H., Daley, M. F., … & Arterburn, D. E. (2019). Safety and effectiveness of longer‐term phentermine use: clinical outcomes from an electronic health record cohort. Obesity, 27(4), 591-602.
- Sorli, C., Harashima, S. I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The lancet Diabetes & endocrinology, 5(4), 251-260.
- Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023). Semaglutide for the treatment of overweight and obesity: a review. Diabetes, Obesity and Metabolism, 25(1), 18-35.
- Hvass, K. C. C. P. S., Rune, I. A. F. J. Z., & Overgaard, V. (2018). Semaglutide sc Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis.
- Han, S. H., Safeek, R., Ockerman, K., Trieu, N., Mars, P., Klenke, A., … & Sorice-Virk, S. (2024). Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google Trends analysis. Aesthetic Surgery Journal, 44(1), 60-67.
- Klonoff, D. C., Bassock, S., Dwyer, A., Engels, E., Qvist, M., Sparre, T., & Snitker, S. (2021). Evaluating the usability and safety of the semaglutide single‐dose pen‐injectors through summative (human factors) usability testing. Journal of Diabetes Investigation, 12(6), 978-987.
- Care, D. (2023). Standards of care in diabetes—2023. Diabetes care, 46, S1-267.
- Tak, Y. J., & Lee, S. Y. (2021). Long-term efficacy and safety of anti-obesity treatment: where do we stand?. Current obesity reports, 10, 14-30.
- Altywaiq, A. M., Alanzi, T. S. N., Al-Ruqi, A. R. M., Alotaibi, W. N., Alnughaythir, A. A. I., Alshammari, S. M., … & Alkhalifah, S. S. (2022). Ozempic and Wegovy for Weight Loss, Pharmacological Component and Effect. Journal of Namibian Studies: History Politics Culture, 31, 167-180.
Read this Next
Do Weight Loss Patches Work?
Weight loss patches are designed for easy weight loss and promise that their active substances are absorbed by skin—transdermally....
Best Prescription Weight-Loss Pills?
The process of slimming appears to turn into a stressful event because there is a tendency to jump from...
Does Medicare Cover Wegovy, Zepbound, and Other Weight-Loss Medications?
Overweight and obesity are among the most important issues affecting health of population in the United States, especially of...
Zepbound vs Wegovy
If you’ve been exploring weight loss options, you might have come across two newer treatments: ZepBound and Wegovy. These...